at a glance
Malaria | Multi-stage
01 November 2023 to 30 April 2028
European Vaccine Initiative
8.2 Mio Euro
Correlates of Protective immunity-driven investigation of malaria vaccine combination strategies
CAPTIVATE will develop a new and improved vaccine targeting multiple developmental stages of P. falciparum, the most dangerous form of the malaria parasite. The consortium will optimise the efficacy of current pre-erythrocytic vaccines while evaluating the safety and immunogenicity of new blood-stage mRNA vaccine candidates, from pre-clinical testing to an early-stage clinical trial.
In parallel, the consortium will work on developing the next generation of highly efficacious malaria vaccine candidates using an advanced in-silico platform to analyse TCR- and single cell sequencing data in combination with artificial intelligence (AI) based predictions of novel malaria vaccine antigens.
The consortium will also establish a European facility for production of malaria sporozoites for research and clinical use.
CAPTIVATE Consortium is comprised with experts in the fields of malaria modelling in primates, clinical vaccine testing, in-silico modelling of immune responses and innovative omics approaches:
-Deutsches Krebsforschungszentrum Heidelberg (Germany)
-European Vaccine Initiative (EVI) (Germany)
-Leiden University Medical Center (Netherlands)
-NEC OncoImmunity (Norway)
-Quantoom biosciences (Belgium)
-Stichting Biomedical Primate Research Center (Netherlands)
-University of New South Wales (Australia)
This project has received funding from the European Union’s Horizon Europe research and innovation programme under grant agreement No 101081028.